1. Market Definition & Product Landscape

1.1 What is Squalene?Squalene is a natural triterpenoid hydrocarbon (C₃₀H₅₀). In humans, it is a precursor of cholesterol and a major component of sebum (roughly 12-13%), providing natural hydration and antioxidant protection to the skin .

1.2 Types by SourceThe market is segmented into three distinct supply chains :

Source Type	Primary Origin	Regulatory Status in EU Cosmetics	2034 Outlook
Animal-Sourced	Shark Liver Oil	Prohibited (Annex II)	Declining / Niche
Plant-Sourced	Olive, Amaranth, Sugarcane	Fully Permitted	Dominant
Biosynthetic	Yeast/Microalgae Fermentation	Fully Permitted	Fastest-Growing

2. Market Dynamics & Forces2.1 Key Drivers

• The “Clean Beauty” Megatrend: Consumers demand vegan, cruelty-free, and sustainably sourced ingredients. Plant-based squalene fits this narrative perfectly .

• Vaccine Adjuvant Demand: The COVID-19 pandemic highlighted squalene’s critical role in enhancing immune response (e.g., MF59 and AS03 adjuvants). R&D in flu and malaria vaccines continues to drive pharmaceutical demand .

• Bioavailability: Squalene is highly absorbable (60-85%) and mimics human sebum, making it superior to many synthetic emollients .

2.2 Industry Challenges

• Supply Chain Ethics: Approximately 3,000 sharks are killed to produce just 1 ton of shark-derived squalene, raising significant extinction concerns .

• Price Volatility: Traditional sourcing relies on fishing yields, whereas plant-based sourcing is subject to agricultural commodity prices.

3. Regional Analysis: The European Stronghold

Europe is not just the largest market; it is the strictest regulator. For any supplier looking to establish credibility, understanding the EU framework is mandatory .

3.1 The EU Cosmetics Regulation (EC) No 1223/2009

• The Ban: Shark-derived squalene is listed under Annex II (Prohibited Substances). This is an absolute barrier to entry for animal-based products in the EU cosmetic sector.

• The Opportunity: Plant-derived and biosynthetic squalene face no restrictions and are the only compliant options for cosmetic manufacturers operating in the EU .

3.2 Pharmaceutical Standards (Ph. Eur.)References

1. Fortune Business Insights. (2026). *Squalene Market Size, Share & Industry Analysis, 2026-2034* .

2. Dasari, D., et al. (2025). Squalene: A High‐Value Compound for COVID‐19 Vaccine Adjuvants and Beyond. IUBMB Life .

3. Global Industry Analysts. (2025). Squalene Market Report .

4. Shalu, S., et al. (2024). Microbial Squalene: A Sustainable Alternative. Engineering in Life Sciences .

5. ScienceDirect. (2024). Recent advances in squalene: Biological activities, sources, extraction, and delivery systems .

For pharma-grade squalene (vaccines), compliance with the European Pharmacopoeia (Monograph 2805) is required. While shark sources are technically still permitted here, major players like Evonik have launched GMP-grade plant-based squalene, setting a new industry benchmark for safety and purity .

3.3 Country Breakdown (2025 Data)

• Germany: The largest single market within Europe, driven by high demand for anti-aging cosmetics.https://www.jxserum.com/other-extracts/

• France: Hub for luxury cosmetics; high demand for “bio” and plant-based certifications.

• UK: Strong post-Brexit independent regulatory framework that mirrors EU standards on animal cruelty .

4. Competitive Landscape & Trade4.1 Key Global Players

The market features a mix of traditional Japanese suppliers and modern biotech innovators :

• Traditional: Kishimoto Special Liver Oil (Japan), Maruha Nichiro (Japan).

• Plant-Based Innovators: Sophim (France), Croda (UK), Amyris (USA – Biosynthetic).

• Emerging Chinese Suppliers: High-purity plant-sourced manufacturers are gaining significant traction, leveraging cost advantages and scalable production.

4.2 The Price Premium Matrix

• Commodity (Shark): High volatility, ethical risks, declining acceptance.

• Value-Added (Plant/Bio): Stable pricing, premium margins (20-30% higher), long-term contracts.

5. Future Outlook & Trends (2026-2034)

1. The Rise of Biosynthetic SqualeneMicrobial fermentation (using engineered yeast or microalgae) is the future. It offers purity independent of weather (agriculture) or fishing quotas, with a lower carbon footprint .

2. Functional Food ExpansionAs studies confirm its cholesterol-lowering and detoxification effects (see ScienceDirect, 2024), squalene is moving beyond capsules into functional beverages and fortified foods.

3. Supply Chain RegionalizationPost-pandemic, buyers are de-risking supply chains. Suppliers offering dual sourcing (e.g., Olive AND Sugarcane) will win over buyers looking for security against crop failures.

6. Strategic Recommendations for Buyers

For procurement managers and R&D directors reading this white paper:

1. Verify Your Source: If you are selling in Europe, ensure your Certificate of Analysis (COA) explicitly states “100% Plant-Derived” . Shark-derived sources are non-compliant.

2. Look for High Purity: For pharmaceutical or high-end cosmetic use, purity requirements exceed 97% . Lower purity requires additional refining.

3. Partner with Integrated Suppliers: Work with suppliers who control the manufacturing process (from crude oil to refined squalene) to ensure traceability.

Conclusion

The global squalene market is at a tipping point. Sustainability is no longer a marketing advantage; it is a regulatory requirement.

For suppliers, the message is clear: Plant-based is the only viable path forward for growth.

For buyers, the time to audit your supply chain is now. Transitioning to plant-derived or biosynthetic squalene mitigates regulatory risk, aligns with ESG goals, and meets the surging consumer demand for ethical beauty and health products.

Media Contact
Company Name: Jiangxi Serum Pharma Industries Co., Ltd.
Email: Send Email
Country: China
Website: https://www.jxserum.com/